Overview

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Ascentage Pharma Group Inc.
Collaborator:
HealthQuest Pharma Inc.